美药厂Regeneron将要求FDA批准旗下新冠治疗药作预防治疗用途
美国药厂Regeneron Pharmaceuticals(REGN.US)表示,将向美国食品及药物管理局(FDA)要求扩大旗下新冠抗体治疗法用作预防性治疗。当局早前已批准有关疗法应用於轻至中度病徵病人,与及有12岁以上未成年高风险病人。
Regeneron表示,其疗法於美国进行的第三阶段临床测试中显示,有效减少出现病徵感染比率达81%。出现病微病人痊癒速度较其他患者快两周。研究邀请1,505名未受感染但同区出现确诊个案的人士参与,41%为拉丁裔、9%为黑人,33%有肥胖症,38%为50岁以上人士,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.